LAVAL, Québec– Altasciences, a fully integrated drug development solutions provider, and VoxCell BioInnovation, a pioneer in 3D bioprinting and human-like tissue modeling, have announced a strategic collaboration to enhance preclinical research and streamline the path from discovery to clinical trials.
By incorporating VoxCell’s high-resolution 3D bioprinted tissue platforms into Altasciences’ discovery and preclinical services, the partnership aims to shorten R&D timelines and improve the success rate of investigational therapies.
This collaboration merges Altasciences’ comprehensive early-phase development expertise with VoxCell’s advanced 3D tissue technology to create a more predictive and human-relevant environment for preclinical testing.
“We’re proud to partner with VoxCell BioInnovation to introduce next-generation tissue modeling into the early stages of drug development,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “This partnership reflects our commitment to the 3Rs—Replacement, Reduction, and Refinement—as well as to innovative, efficient solutions that improve data quality and accelerate decision-making for our clients.”
VoxCell’s proprietary bioprinted tissues are designed to replicate the complexity of human tumors and other biological structures. These advanced models provide pharmaceutical companies with a powerful platform to assess efficacy, safety, and toxicity—prior to advancing to animal or human studies.
“Our mission has always been to make drug screening more predictive and human-relevant,” said Karolina Valente, CEO of VoxCell BioInnovation. “Altasciences shares this forward-thinking approach, and we’re excited to collaborate in helping pharmaceutical and biotech companies make faster, more informed decisions.”
The partnership will initially focus on drug screening for ocular diseases, with plans to expand into additional therapeutic areas over time.
Together, Altasciences and VoxCell are working to redefine early-stage research through innovation, integration, and smarter science—driving better outcomes for patients around the world.
